# Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

> **NCT01514188** · PHASE2 · COMPLETED · sponsor: **ImmunityBio, Inc.** · enrollment: 126 (actual)

## Conditions studied

- Metastatic Soft Tissue Sarcoma
- Locally Advanced Soft Tissue Sarcoma
- Unresectable Soft Tissue Sarcoma

## Interventions

- **DRUG:** INNO-206
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT01514188
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-11
- **Primary completion:** 2014-04-09
- **Final completion:** 2014-12-15
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2024-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01514188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01514188, "Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01514188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*